Market LIVE
Published markets; coverage varies by country
Product profile · United States

QUILLICHEW ER

 ·  Patent Litigation & Settlement History ↓

IngredientMETHYLPHENIDATE HYDROCHLORIDE
Application typeNDA
Application207960
Product001
Dosage formTABLET, EXTENDED RELEASE, CHEWABLE
RouteORAL
Strength20MG
Approval date2015-12-04
Marketing statusRX
Status event—
ApplicantNEXTWAVE PHARMS
Product source

Current GenericRadar decision

Year2018
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2018-12-04
Patent anchor—
Exclusivity anchor2018-12-04
Protection date2033-08-14
First Final ANDA—
Status event—

Rights after the canonical full-scope anchor require DEEP_REVIEW.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
82025372027-03-15DP —NNFORMULATION
———
82025372027-03-15DP —NNFORMULATION
Methylphenidate modified-release tablet with resin matrix and cured barrier coating.
———
82879032031-02-15DP —NNFORMULATION
———
82879032031-02-15DP —NNFORMULATION
Methylphenidate resin-complex suspension, powder blend or solid dose with barrier coating, pH and release-profile limits.
———
108571432033-08-14DP/U U-2993NNFORMULATION
———
108571432033-08-14DP/U U-2993NNFORMULATION
Methylphenidate resin-complex chewable tablet with coated sustained-release and immediate-release proportions.
———
111034942033-08-14DP —NNFORMULATION
———
111034942033-08-14DP —NNFORMULATION
Extended-release methylphenidate resin-complex tablet with coated/IR components and PK restrictions.
———
111034952033-08-14DP/U U-2993NNFORMULATION
———
111034952033-08-14DP/U U-2993NNFORMULATION
Divisible chewable methylphenidate tablet using specific resin, matrix, barrier coating and component ratios.
———
116333892033-08-14DP —NNFORMULATION
———
116333892033-08-14DP —NNFORMULATION
Methylphenidate chewable resin-complex tablet with coating and sustained/immediate-release proportions.
———
89993862033-08-14DP —NNFORMULATION
———
89993862033-08-14DP —NNFORMULATION
Methylphenidate chewable tablet with resin matrix, multiple release components and PK constraints.
———
92956422033-08-14DP/U U-1827NNFORMULATION
———
92956422033-08-14DP/U U-1827NNFORMULATION
Methylphenidate chewable resin-complex tablet with multiple release components and PK restrictions.
———
95453992033-08-14DP/U U-1827NNFORMULATION_USE
———
95453992033-08-14DP/U U-1827NNFORMULATION_USE
Methylphenidate ER chewable resin-complex tablet with coating, release proportions and PK limits; use claims depend on that tablet.
———
98445442033-08-14DP/U U-2203NNFORMULATION_PK
———
98445442033-08-14DP/U U-2203NNFORMULATION_PK
Independent method and product claims require methylphenidate resin complexes, barrier coatings, release proportions and PK conditions.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NP2015-12-042018-12-04New methylphenidate extended-release chewable product for ADHD; all approved patient ages and strengths in this queue are covered by the product-level change.YY2018-12-04Source

2026-10-11 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
214202 / 001APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED——TEVA PHARMS USANEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (12)
TypeDateRoleBasisSource
PATENT2027-03-15FTO_TAILMethylphenidate modified-release tablet with resin matrix and cured barrier coating.Source
PATENT2031-02-15FTO_TAILMethylphenidate resin-complex suspension, powder blend or solid dose with barrier coating, pH and release-profile limits.Source
PATENT2033-08-14FTO_TAILExtended-release methylphenidate resin-complex tablet with coated/IR components and PK restrictions.Source
PATENT2033-08-14FTO_TAILMethylphenidate resin-complex chewable tablet with coated sustained-release and immediate-release proportions.Source
PATENT2033-08-14FTO_TAILMethylphenidate chewable resin-complex tablet with coating and sustained/immediate-release proportions.Source
PATENT2033-08-14FTO_TAILIndependent method and product claims require methylphenidate resin complexes, barrier coatings, release proportions and PK conditions.Source
PATENT2033-08-14FTO_TAILMethylphenidate ER chewable resin-complex tablet with coating, release proportions and PK limits; use claims depend on that tablet.Source
PATENT2033-08-14FTO_TAILDivisible chewable methylphenidate tablet using specific resin, matrix, barrier coating and component ratios.Source
PATENT2033-08-14FTO_TAILMethylphenidate chewable tablet with resin matrix, multiple release components and PK constraints.Source
PATENT2033-08-14FTO_TAILMethylphenidate chewable resin-complex tablet with multiple release components and PK restrictions.Source
REGULATORY_EXCLUSIVITY2018-12-04CANONICAL_ANCHORNew methylphenidate extended-release chewable product for ADHD; all approved patient ages and strengths in this queue are covered by the product-level change.Source
REGULATORY_STATUS2018-12-04DECISION_BASISRights after the canonical full-scope anchor require DEEP_REVIEW.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.